Remission Induction and Sustenance in Graves' Disease 2

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Peter Laurberg, Aalborg Hospital
ClinicalTrials.gov Identifier:
NCT00796913
First received: November 21, 2008
Last updated: January 22, 2013
Last verified: January 2013

November 21, 2008
January 22, 2013
January 2008
January 2015   (final data collection date for primary outcome measure)
Relapse of hyperthyroidism [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00796913 on ClinicalTrials.gov Archive Site
Reoccurrence of TSH-receptor autoimmunity [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Remission Induction and Sustenance in Graves' Disease 2
Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy

ATD therapy for Graves' disease is one of the commonly used options for therapy of the hyperthyroidism. The investigators study how to optimally keep patients in remission.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Graves Disease
  • Hyperthyroidism
Other: Stop medication
Stop medication Stop medication + se supplement
Other Names:
  • stop medication
  • stop medication + se supplement
  • Active Comparator: Stop of medication after remission
    Intervention: Other: Stop medication
  • No Intervention: Medication for 2 yrs after remission
  • Experimental: Se-yeast 200 Microgr/day + arm A
    Intervention: Other: Stop medication
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
250
January 2016
January 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Graves hyperthyroidism in remission after ATD

Exclusion Criteria:

  • Age < 18, severe concomitant disease
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00796913
RISG2
Not Provided
Peter Laurberg, Aalborg Hospital
Aalborg Universityhospital
Not Provided
Principal Investigator: Peter Laurberg, MD Aalborg Universityhospital
Aalborg Universityhospital
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP